China province Sichuan covid-19 information vaccine China province Sichuan

CEPI expands Covid-19 vaccine alliance with Clover Biopharmaceuticals

Reading now: 188
www.pharmaceutical-technology.com

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The Coalition for Epidemic Preparedness Innovations (CEPI) has expanded its collaboration with China-based Sichuan Clover Biopharmaceuticals to speed-up the development and manufacture of Covid-19 vaccine candidate.

Clover’s S-Trimer vaccine candidate is based on its Trimer-Tag vaccine platform. In April, CEPI agreed to provide $3.5m funding support to prepare and launch a Phase I trial of Clover’s vaccine.

As part of the expanded alliance, CEPI will provide an additional $66m upfront for immediate funding of preclinical studies, to carry out Phase I clinical trials and prepare sites worldwide for an efficacy trial.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA